Leerink Partnrs Lowers Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Kura Oncology in a note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of $0.15 for the quarter, down from their previous estimate of $0.16. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

KURA has been the topic of a number of other research reports. StockNews.com downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Barclays lowered their price target on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $23.89.

Kura Oncology Trading Up 1.2%

NASDAQ KURA opened at $6.02 on Monday. The stock’s 50-day simple moving average is $6.42 and its two-hundred day simple moving average is $8.72. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $521.18 million, a price-to-earnings ratio of -2.55 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BVF Inc. IL increased its holdings in Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock valued at $51,177,000 after purchasing an additional 5,186,660 shares during the period. Armistice Capital LLC boosted its position in Kura Oncology by 13.3% during the 1st quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock valued at $43,375,000 after acquiring an additional 772,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company’s stock valued at $32,658,000 after acquiring an additional 129,337 shares in the last quarter. RA Capital Management L.P. bought a new stake in Kura Oncology during the 4th quarter valued at approximately $38,769,000. Finally, Millennium Management LLC boosted its position in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after acquiring an additional 1,521,954 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.